TY - JOUR T1 - Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines JF - The Journal of Rheumatology JO - J Rheumatol SP - 1385 LP - 1389 DO - 10.3899/jrheum.220469 VL - 49 IS - 12 AU - Carolina A. Isnardi AU - Osvaldo L. Cerda AU - Margarita Landi AU - Leonel Cruces AU - Emilce E. Schneeberger AU - Claudia Calle Montoro AU - María Agustina Alfaro AU - Brian M. Roldán AU - Andrea B. Gómez Vara AU - Pamela Giorgis AU - Roberto Alejandro Ezquer AU - María G. Crespo Rocha AU - Camila R. Reyes Gómez AU - Mária de los Ángeles Correa AU - Marcos G. Rosemffet AU - Virginia Carrizo Abarza AU - Santiago Catalan Pellet AU - Miguel Perandones AU - Cecilia Reimundes AU - Yesica Longueira AU - Gabriela Turk AU - María Florencia Quiroga AU - Natalia Laufer AU - Rosana Quintana AU - María Celina de la Vega AU - Nicolás Kreplak AU - Marina Pifano AU - Pablo Maid AU - Guillermo J. Pons-Estel AU - Gustavo Citera Y1 - 2022/12/01 UR - http://www.jrheum.org/content/49/12/1385.abstract N2 - Objective The aim of this study was to assess the immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibody titers after the primary regimen of 2 doses.Methods Patients with RA with no seroconversion after 2 doses of SARS-CoV-2 vaccine and who received a third dose of either an mRNA or vector-based vaccine were included. Anti-SARS-CoV-2 IgG antibodies, neutralizing activity, and T cell responses were assessed after the third dose.Results A total of 21 nonresponder patients were included. At the time of vaccination, 29% were receiving glucocorticoids and 85% biologic disease-modifying antirheumatic drugs (including 6 taking abatacept [ABA] and 4 taking rituximab [RTX]). The majority (95%) received the BNT162b2 vaccine and only one of them received the ChAdOx1 nCoV-19 vaccine. After the third dose, 91% of the patients presented detectable anti-SARS-CoV-2 IgG and 76% showed neutralizing activity. Compared to other treatments, ABA and RTX were associated with the absence of neutralizing activity in 4 out of 5 (80%) patients and lower titers of neutralizing antibodies (median 3, IQR 0-20 vs 8, IQR 4-128; P = 0.20). Specific T cell response was detected in 41% of all patients after the second dose, increasing to 71% after the third dose. The use of ABA was associated with a lower frequency of T cell response (33% vs 87%, P = 0.03).Conclusion In this RA cohort, 91% of patients who failed to seroconvert after 2 doses of SARS-CoV-2 vaccine presented detectable anti-SARS-CoV-2 IgG after a third dose. The use of ABA was associated with a lower frequency of specific T cell response. ER -